Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells

Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer

(2015) Petronella O. Witteveen et al.   NEOPLASIA

Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

(2015) Sun-Jin Kim et al.   NEOPLASIA

Antivascular Therapy for Multidrug-Resistant Ovarian Tumors by Macitentan, a Dual Endothelin Receptor Antagonist

(2014) Sun-Jin Kim et al.   Translational Oncology

Ovarian cancer stem cell markers: Prognostic and therapeutic implications

(2012) Daniela Burgos-Ojeda et al.   CANCER LETTERS

Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival

(2011) I. A. Silva et al.   CANCER RESEARCH

Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells

(2011) L. Rosano et al.   CLINICAL CANCER RESEARCH

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

(2011) Patricia N. Sidharta et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

(2010) Nicholas D. James et al.   BJU INTERNATIONAL

F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial Cells In vivo

(2010) I. Winer et al.   CANCER RESEARCH

Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer

(2010) C. N. Landen et al.   MOLECULAR CANCER THERAPEUTICS

Endothelin receptor antagonism and cancer

(2009) A. Bhalla et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer

(2009) Heather L Pulaski et al.   Journal of Translational Medicine

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

(2008) T Baba et al.   ONCOGENE

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE